AGM/EGMApr 28, 2026, 05:02 PM
TBPH Board Reduced to 6 Directors; Declassified
AI Summary
Theravance Biopharma, Inc. announced its 2026 Annual General Meeting to be held on June 12, 2026, in Dublin, Ireland. The company plans to reduce its board of directors from nine to six members and declassify the board, with all directors serving one-year terms. Shareholders will vote on the election of six nominated directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, and a non-binding advisory resolution regarding executive compensation.
Key Highlights
- 2026 Annual General Meeting scheduled for June 12, 2026, at 5:00 pm Irish Time.
- Board of directors to be reduced from nine to six members.
- Board of directors to be declassified, with all directors serving one-year terms.
- Six directors nominated for election: Laurie Smaldone Alsup, Susannah Gray, Dean J. Mitchell, Donal O’Connor, Deepika R. Pakianathan, and Rick E Winningham.
- Shareholders to ratify Ernst & Young LLP as independent auditor for fiscal year 2026.
- Non-binding advisory vote on named executive officer compensation.
- Record date for voting is April 13, 2026.
- Proxy materials and 2025 Annual Report on Form 10-K available online.
Price Impact
More from TBPH